Antiphospholipid antibodies correlate with stroke severity and outcome in patients with antiphospholipid syndrome. (August 2015)

• Record Type: Journal Article
• Authors: Rodríguez-Sanz, Ana; Martínez-Sánchez, Patricia; Prefasi, Daniel; Fuentes, Blanca; Pascual-Salcedo, Dora; Blanco-Bañares, María Jesús; Díez-Tejedor, Exuperio
• Is Part Of: Autoimmunity. Volume 48:Number 5(2015)
• Page Start: 275
• Page End: 281
• Publication Date: 2015-08
• Subjects: Autoimmunity -- Periodicals; Autoimmune diseases -- Periodicals; 571.973
• DOI: 10.3109/08916934.2014.988329
• Languages: English
• ISSNs: 0891-6934

Abstract

<abstract> <title>Abstract</title> <p> <italic>Background</italic>: Our goal was to analyze the association of the level of antiphospholipid antibodies (aPLs) with stroke severity and outcome in patients with antiphospholipid syndrome (APS). <italic>Methods</italic>: Observational study included consecutive patients with ischemic stroke younger than 55 years (2007–2012). We analyzed serum levels of aPLs, including anticardiolipin (aCL) antibodies, anti-β2-glycoprotein I antibodies (anti-β2GPI) and antiprothrombin antibodies (aPS/PT) within the first 48 h after admission, and again, in the case of a positive result, at least 12 weeks after the first measurement. Stroke severity was measured by the National Institutes of Health Stroke Scale (NIHSS), and the three-month stroke outcome by the modified Rankin Scale (mRS). Multiple linear regression models were used to analyze the correlation between the aPLs and stroke severity and outcome. <italic>Results</italic>: Overall 255 stroke patients were included, 22 (8.6%) with APS. Among them, a positive correlation was found between immunoglobulin M (IgM) aCL levels within 48 h and NIHSS (rho = 0.471; <italic>p</italic> = 0.027), as well as a tendency toward a positive correlation between immunoglobulin G (IgG) anti-β2GPI levels within 48 h and three-month mRS (rho = 0.364; <italic>p</italic> = 0.096). Multiple linear regression analyses showed a positive correlation between levels of IgM aCL < 48 h and the NIHSS (<italic>β</italic>-coefficient [standard error; SE] = 0.127 [0.044]), as well as the levels of IgG anti-β2GPIwithin 48 h and the three-month mRS (<italic>β</italic>-coefficient [SE] = 0.034 [0.011]). <italic>Conclusions</italic>: In young stroke patients with APS, serum levels of IgM aCL within 48 h are correlated with stroke severity and levels of IgG anti-β2GPI within 48 h are correlated with three-month outcomes.</p> </abstract>